Ancestral SARS-CoV-2-Driven Antibody Repertoire Diversity in an Unvaccinated Individual Correlates with Expanded Neutralization Breadth-Reference-Cited by-同舟云学术

Ancestral SARS-CoV-2-Driven Antibody Repertoire Diversity in an Unvaccinated Individual Correlates with Expanded Neutralization Breadth

Published:2023-04-13 Issue:2 Volume:11 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Deshpande Suprit¹,Ansari Mohammed Yousuf¹,Sutar Jyoti¹²,Das Payel¹,Hingankar Nitin¹,Mukherjee Sohini¹²,Jayal Priyanka¹,Singh Savita³,Anantharaj Anbalagan³⁴,Singh Janmejay³⁴,Chattopadhyay Souvick³,Raghavan Sreevatsan³,Gosain Mudita³,Chauhan Supriya¹,Shrivas Shweta¹,Prasad Chaman¹,Chauhan Sangeeta¹,Sharma Neha¹,Jana Pradipta³,Thiruvengadam Ramachandran³,Kshetrapal Pallavi³,Wadhwa Nitya³,Das Bhabatosh³,Batra Gaurav³,Medigeshi Guruprasad³⁴^ORCID,Sok Devin⁵⁶²,Bhatnagar Shinjini³,Garg Pramod Kumar³,Bhattacharya Jayanta¹²^ORCID

Affiliation:

1. IAVI-Antibody Translational Research Program, Translational Health Science & Technology Institute, Faridabad, Haryana, India

2. IAVI, New York, New York, USA

3. Translational Health Science & Technology Institute, Faridabad, Haryana, India

4. Bioassay Laboratory, Translational Health Science & Technology Institute, Faridabad, Haryana, India

5. IAVI-Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, USA

6. Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, USA

Abstract

Development of robust neutralizing antibodies in SARS-CoV-2 convalescent individuals is known; however, it varies at the population level. We isolated monoclonal antibodies from an individual infected with ancestral SARS-CoV-2 in early 2020 that not only varied in their B cell lineage origin but also varied in their capability and potency to neutralize all the known variants of concern (VOCs) and currently circulating Omicron variants.

Funder

Norges Forskningsråd

Bill and Melinda Gates Foundation

Department of Biotechnology, Ministry of Science and Technology, India

Indian Council of Medical Research

The Wellcome Trust DBT India Alliance

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.04332-22

Reference20 articles.

1. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum

2. Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2

3. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

4. Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5

5. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum